NeuroSense has secured a South Korean patent for PrimeC, an oral combination therapy targeting neuroinflammation and oxidative stress in ALS, extending intellectual property protection through 2042. Phase 2b data demonstrated disease progression slowing and survival benefit, positioning the candidate for pivotal Phase 3 trials.
Key Points
- PrimeC combines ciprofloxacin and celecoxib to address three ALS pathways simultaneously
- Phase 2b PARADIGM study showed meaningful slowing of disease progression and survival benefit
- South Korean patent grant follows approvals in Japan, Brazil, Australia, and the United States
Longevity Analysis
ALS represents a neurodegenerative state where multiple interference pathways accelerate decline: neuroinflammation, oxidative stress, and iron dysregulation. PrimeC's mechanism addresses these overlapping drivers rather than targeting a single pathway, a departure from conventional ALS drug development. The Phase 2b biomarker data—including microRNA shifts—suggest the combination can modulate the underlying degenerative cascade, not merely manage symptoms. For practitioners evaluating neuroprotective interventions, this validates a multi-target approach to halting progressive neurological loss, particularly where inflammation and metabolic stress compound tissue damage.
Original published by Longevity.Technology.